BioSpace News Archive

The new CAR-T immunotherapy owned by Bristol-Myers Squib is scheduled for FDA review by December 31, 2020.

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” and the “Company”) today announced that the Company will host a teleconference to discuss its Third Quarter 2020 financial results and to provide a business update

Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference, which takes place November 30 – December 3, 2020.

HealthEquity, Inc., the largest independent HSA custodian, announced plans to release its third quarter fiscal year 2021 financial results following the close of regular stock market trading hours on Monday, December 7, 2020.

PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”)

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test - NeXT DxTM - at the virtual AMP Annual Meeting from Nov 16-20, 2020.

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMX0035 for the treatment of Wolfram syndrome. “There is a critical unmet need for people living with Wolfram syndrome, a r

HealthCore, an outcomes research company of Anthem, Inc., is managing a new study to help understand and combat the pediatric public health emergency arising from the COVID-19 pandemic.

Revelation Biosciences Inc. (Revelation), a clinical stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease, announced today that the first cohort of its Phase 1 clinical study of REVTx‑99 in healthy volunteers (RVL‑NHV01 study) has completed dosing. Eight study participants were dosed with REVTx-9

Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”) , a precision oncology molecular profiling company with a novel phosphoprotein-based laboratory developed test (LDT), today announced its partnership with Perthera , a market leader in Precision Oncology technology and services. The alliance will facilitate and accele